Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 2/20 | 0.46 |
| ▸ | CDC25A | P30304 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15377348 | 1.00 | TDP1 (0.67) | TDP1GAARECQLALDH1A1NR1H2 | |
| SCHEMBL26346465 | 1.00 | TDP1 (0.67) | TDP1GAARECQLALDH1A1NR1H2 | |
| SCHEMBL9282228 | 1.00 | TDP1 (0.67) | TDP1GAARECQLALDH1A1NR1H2 | |
| SCHEMBL31578910 | 1.00 | TDP1 (0.67) | TDP1GAARECQLALDH1A1NR1H2 | |
| SCHEMBL3084331 | 1.00 | TDP1 (0.67) | TDP1GAARECQLALDH1A1NR1H2 | |
| SCHEMBL30538659 | 1.00 | TDP1 (0.67) | TDP1GAARECQLALDH1A1NR1H2 | |
| SCHEMBL4308548 | 1.00 | TDP1 (0.67) | TDP1GAARECQLALDH1A1NR1H2 | |
| SCHEMBL1537376 | 0.98 | TDP1 (0.69) | TDP1GAARECQLALDH1A1NR1H2 | |
| SCHEMBL14560518 | 0.93 | TDP1 (0.76) | TDP1GAARECQLALDH1A1NR1H2 | |
| SCHEMBL12290556 | 0.92 | TDP1 (0.66) | TDP1GAARECQLALDH1A1NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230256098-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2023-08-17 | — | — | US | disclosed |
| US-20230256098-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2023-08-17 | — | — | US | disclosed |
| US-11679158-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11679158-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11633479-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220347302-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2022-11-03 | — | — | US | disclosed |
| US-20220175928-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2022-06-09 | — | — | US | disclosed |
| US-20220125927-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2022-04-28 | — | — | US | disclosed |
| US-11246933-B1 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-11071784-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-10369226-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20150273068-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2015-10-01 | — | — | US | disclosed |
| US-20150273068-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2015-10-01 | — | — | US | disclosed |
| US-9061063-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9061063-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20130195920-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130195920-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| WO-2013086354-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11633479-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | TDP1 1779/4885GAA 253/4885RECQL 1613/4885 |
| US-20130195920-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | TDP1 1779/4885GAA 253/4885RECQL 1613/4885 |
| US-20150273068-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | TDP1 1779/4885GAA 253/4885RECQL 1613/4885 |
| US-10369226-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | TDP1 1779/4885GAA 253/4885RECQL 1613/4885 |
| US-20220347302-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | TDP1 1779/4885GAA 253/4885RECQL 1613/4885 |
| US-20220175928-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | TDP1 1779/4885GAA 253/4885RECQL 1613/4885 |
| US-11246933-B1 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | TDP1 1779/4885GAA 253/4885RECQL 1613/4885 |
| US-11679158-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | TDP1 1779/4885GAA 253/4885RECQL 1613/4885 |
| US-20230256098-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | TDP1 1779/4885GAA 253/4885RECQL 1613/4885 |
| US-20220125927-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | TDP1 1779/4885GAA 253/4885RECQL 1613/4885 |
| US-11071784-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | TDP1 1779/4885GAA 253/4885RECQL 1613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.